Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180,078 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl cis-trans isomerase activity: direct binding between CyPA and the ectodomain of CD147.
Song F, Zhang X, Ren XB, Zhu P, Xu J, Wang L, Li YF, Zhong N, Ru Q, Zhang DW, Jiang JL, Xia B, Chen ZN. Song F, et al. Among authors: zhang dw, zhang x. J Biol Chem. 2011 Mar 11;286(10):8197-8203. doi: 10.1074/jbc.C110.181347. Epub 2011 Jan 18. J Biol Chem. 2011. PMID: 21245143 Free PMC article.
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.
Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, Yin R, Wu X, Yao S, Gu K, Zhang H, Li G, Pan H, Wu Q, An R, Yang X, Zhu Y, Wan X, Duan W, Xiong J, Guo H, Lou G, Wang J, Hu W, Zhang X, Meng Y, Zhang B, Wang Y, Wang Q, Wu L. Li N, et al. Among authors: zhang b, zhang h, zhang x. Clin Cancer Res. 2021 May 1;27(9):2452-2458. doi: 10.1158/1078-0432.CCR-20-3546. Epub 2021 Feb 8. Clin Cancer Res. 2021. PMID: 33558426 Clinical Trial.
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L. Li N, et al. Among authors: zhang b, zhang s, zhang g, zhang x, zhang y. J Clin Oncol. 2022 Aug 1;40(22):2436-2446. doi: 10.1200/JCO.21.01511. Epub 2022 Apr 11. J Clin Oncol. 2022. PMID: 35404684 Clinical Trial.
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.
Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W, Weisberg EL, Liu J, Liu Q. Liu X, et al. Among authors: zhang s, zhang x. Oncotarget. 2016 May 31;7(22):32641-51. doi: 10.18632/oncotarget.8702. Oncotarget. 2016. PMID: 27081697 Free PMC article.
Discovery of a Highly Selective STK16 Kinase Inhibitor.
Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W, Zhao Z, Wang A, Chen Y, Wang L, Gray NS, Liu J, Zhang X, Liu Q. Liu F, et al. Among authors: zhang x. ACS Chem Biol. 2016 Jun 17;11(6):1537-43. doi: 10.1021/acschembio.6b00250. Epub 2016 Apr 22. ACS Chem Biol. 2016. PMID: 27082499
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
Liu X, Wang A, Liang X, Liu J, Zou F, Chen C, Zhao Z, Deng Y, Wu H, Qi Z, Wang B, Wang L, Liu F, Xu Y, Wang W, Fernandes SM, Stone RM, Galinsky IA, Brown JR, Loh T, Griffin JD, Zhang S, Weisberg EL, Zhang X, Liu J, Liu Q. Liu X, et al. Among authors: zhang s, zhang x. Oncotarget. 2016 Aug 16;7(33):53515-53525. doi: 10.18632/oncotarget.10650. Oncotarget. 2016. PMID: 27447747 Free PMC article.
180,078 results
You have reached the last available page of results. Please see the User Guide for more information.